Shuang Qi
Jinan 250014, PR China
Puerto Rico
Puerto Rico
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
A novel EGFR-targeted photosensitizer for the theranostics of skin cancer.
Journal: International journal of pharmaceutics: X
Published: July 02, 2025
Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs.
Journal: Nature communications
Published: January 24, 2025
Discovery of dihydropyridinone derivative as a covalent EZH2 degrader.
Journal: European journal of medicinal chemistry
Published: July 26, 2023
Discovery of Pyrazolo[1,5-a]pyrimidine derivative as a potent and selective PI3Kγ/δ dual inhibitor.
Journal: European journal of medicinal chemistry
Published: May 29, 2023
Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.
Journal: European journal of pharmacology
Published: February 25, 2023
Turn-off near-infrared fluorescent probe for free bilirubin detection constructed by enhanced excimer emission.
Journal: Analytica chimica acta
Published: September 27, 2022
Discovery of Pyrrolo[2,3-d]pyrimidine derivatives as potent and selective colony stimulating factor 1 receptor kinase inhibitors.
Journal: European journal of medicinal chemistry
Published: August 03, 2022
Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2.
Journal: Leukemia
Published: September 01, 2021
Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.
Journal: European journal of medicinal chemistry
Published: May 16, 2020
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.
Journal: Experimental cell research
Published: November 19, 2019
Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models.
Journal: Cancer letters
Published: September 30, 2018
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Journal: European journal of medicinal chemistry
Published: September 18, 2017
Showing 1-12 of 12
Last Updated: 09/26/2026